Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Article 2017 en
Authors
RH
Rury R. Holman
MB
M. Angelyn Bethel
RM
Robert J. Mentz
Abstract
1 min read
Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .).
Robert J. Mentz, M. Angelyn Bethel, Peter Merrill, Yuliya Lokhnygina, John B. Buse, Juliana C.N. Chan, João Soares Felício, Shaun G. Goodman, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Renato D. Lópes, Aldo Maggioni, Peter Öhman, Neha J. Pagidipati, Neil R Poulter, Ambady Ramachandran, Barry Reicher, Rury R. Holman, Adrian F. Hernandez
Dick de Zeeuw, Tadao Akizawa, Paul Audhya, George L. Bakris, Melanie Chin, Heidi Christ‐Schmidt, Angie Goldsberry, Mark T. Houser, Melissa Krauth, Hiddo J.L. Heerspink, John J.V. McMurray, Colin J. Meyer, Hans‐Henrik Parving, Giuseppe Remuzzi, Robert D. Toto, Nosratola D. Vaziri, Christoph Wanner, Janet Wittes, Danielle Wrolstad, Glenn M. Chertow
Marc A. Pfeffer, Brian Claggett, Rafael Díaz, Kenneth Dickstein, Hertzel C. Gerstein, Lars Køber, Francesca Lawson, Lin Ping, Xiaodan Wei, Eldrin F. Lewis, Aldo Maggioni, John J.V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Scott D. Solomon, Jean‐Claude Tardif
M. Angelyn Bethel, Robert J. Mentz, Peter Merrill, John B. Buse, Juliana C.N. Chan, Shaun G. Goodman, Nayyar Iqbal, Neli Jakubonienė, Brian G. Katona, Yuliya Lokhnygina, Renato D. Lópes, Aldo Maggioni, Peter K. Öhman, Neil R Poulter, Ambady Ramachandran, Tsvetalina Tankova, Bernard Zinman, Adrian F. Hernandez, Rury R. Holman
Discussion(0)
No comments yet. Be the first to comment.